7HP-349 is under clinical development by 7 Hills Pharma and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how 7HP-349’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

7HP-349 overview

7HP-349 is under development for the treatment of metastatic melanoma, hematopoietic stem cell transplantation, influenza and solid tumors. It is administered through oral route. The drug candidate is a softgel capsule, which acts as activators of VLA-4 and LFA-1 cell adhesion axes. The drug candidate acts by targeting integrin.

7 Hills Pharma overview

7 Hills Pharma is a clinical stage pharmaceutical company, that develops first-in-concept integrin activators to augment immunotherapies for the treatment of drug resistant solid tumors and infectious diseases. 7 Hills Pharma is headquartered in Houston, Texas, the US.

For a complete picture of 7HP-349’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 15 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.